X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development

Developing Drugs That Target Multidrug-Resistant Bacteria

Content Team by Content Team
28th December 2022
in Drug Development, News
Developing Drugs That Target Multidrug-Resistant Bacteria

Antibiotic usage is crucial in the treatment of many bacterial infections. However, the quantity of bacteria strains that are impervious to numerous antibiotics is increasing as a result of ongoing overuse and misuse, which is hurting millions of people worldwide. The development of novel antibacterial compounds that target different bacteria that are drug-resistant is another important area of research.

The creation of fresh antibiotics has been the focus of a team at Hokkaido University under the direction of Professor Satoshi Ichikawa. Their most recent study describes the creation of a potent antibacterial chemical that is efficient against the most prevalent multidrug-resistant bacteria, and it was released in the journal Nature Communications.

The group focused on the sphaerimicins class of antibacterial substances. The MraY protein cannot carry out its function in the bacteria as a result of these chemicals. MraY is necessary for bacterial replication and participates in the production of the bacterial cell wall; it is not a target of the commercial antibiotics that are currently on the market. Ichikawa, a contributing author of the paper, stated that sphaerimicins are biological chemicals and have very complicated structures. Their goal was to develop analogues of this chemical that would be simpler to produce and more potent against MraY, hence enhancing its antibacterial action. Two of the more prevalent multi-drug-resistant bacteria, methicillin-resistant Staphylococcus aureus (MRSA) as well as vancomycin-resistant Enterococcus faecium (VRE), were successfully treated with the medications they developed.

The researchers developed and synthesised two sphaerimicin analogues, SPM1 and SPM2, and used molecular modelling and calculations to analyse the structures of sphaerimicin A. It was discovered that these analogues were efficient versus Gram positive bacteria. The composition of SPM1 linked to MraY was then established. They discovered ways to further streamline the molecules by examining this structure and contrasting it to that of comparable antibacterial medicines. They were able to develop SPM3, a less complex counterpart with similar action to SPM1.

The SPMs were successful against Mycobacterium tuberculosis, the germ that causes tuberculosis and has multidrug-resistant strains, in addition to MRSA and VRE. The development of the basic skeleton of sphaerimicin, which can be leveraged to create further antibacterial drugs that target MraY and subsequently multidrug-resistant organisms, is their most important contribution. The most promising drug is sphaerimicin because MraY is also found in Gram-negative bacteria, according to Ichikawa. A future study will focus on improving the SPM molecules now in development and creating antibiotic combinations incorporating sphaerimicin to target a larger variety of bacteria.

Previous Post

Elranatamab Causes Recurrent Multi-Myeloma Clinical Response

Next Post

Global Alliance Finds Genetic Cause of Neurological Disease

Related Posts

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Drugs Gain From Tardigrade Proteins, Says Research
Drug Development

Pharma Drugs Gain From Tardigrade Proteins, Says Research

22nd March 2023
Next Post

Global Alliance Finds Genetic Cause of Neurological Disease

Latest News

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In